|
Dec 4
|
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
|
|
Dec 1
|
Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?
|
|
Sep 12
|
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
|
|
Sep 11
|
J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe
|
|
Sep 8
|
Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound?
|
|
Sep 8
|
Exelixis, Inc. (NASDAQ:EXEL) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
|
|
Sep 7
|
J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit
|
|
Sep 6
|
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication
|